ReviewPost screenInflammation in pulmonary hypertension: what we know and what we could logically and safely target first
Introduction
Pulmonary arterial hypertension (PAH) is a devastating disease in which pulmonary vascular remodeling leads to an increased pulmonary vascular resistance resulting in right-heart failure and early death (Fig. 1). It is understood that inflammation and autoimmunity can contribute to PAH pathobiology (Fig, 1, Box 1). The main expected action of current PAH therapeutics is the decrease in pulmonary vascular resistance through the induction of pulmonary artery vasodilatation (prostacyclin analogs, endothelin receptor antagonists, phosphodiesterase type 5 inhibitors and soluble guanylate cyclase stimulators) 1, 2. These treatments do not however afford a cure, and mainly only relieve symptoms and improve health-related quality of life in PAH patients. Thus, new treatments interfering with different mechanisms of PAH pathobiology are required to block disease progression. The presence of pulmonary vascular inflammation and, more specifically, of an adaptive immune response characterized by pulmonary lymphoid neogenesis in PAH patients [3] indicates that new drugs targeting the immunological component of the disease could be considered. As a proof of concept there is evidence that the current PAH therapeutics could have immunomodulatory properties and case reports have suggested that immunosuppressive agents and several targeted immunotherapeutic approaches could improve PAH. Here, we review and evaluate these three aspects of immunomodulatory approaches in PAH.
Section snippets
Anti-inflammatory therapies in autoimmune-disease-associated PAH
Recent reviews have focused on evidence of inflammation in PAH and highlighted the role of inflammation and autoimmunity into disease pathophysiology 4, 5, 6, 7. These highlight the potential of immunotherapy to control disease outcome, and even the treatment of at-risk patients such as those with connective tissue disease or infectious diseases. Immunosuppressive drugs have been widely tested in experimental models of PAH. Not surprisingly, immunosuppressive agents such as dexamethasone,
Immunomodulatory properties of current specific PAH therapeutics
Currently, three pathological pathways are targeted (the endothelin, nitric oxide and prostacyclin pathways) and four classes of therapeutic drugs specific to PAH are available: prostacyclin (epoprostenol) and its analogs (treprostinil, iloprost, beraprost); endothelin receptor antagonists (bosentan, ambrisentan, macitentan); phosphodiesterase type 5 inhibitors (PDE5i) (sildenafil, tadalafil); and soluble guanylate cyclase stimulators (riociguat). All these treatments act on endothelial
Targeted immunotherapy in idiopathic PAH
Although current PAH treatments possess immunomodulatory properties [6], there is no approved therapeutic specifically targeting the inflammatory processes. However, some case studies demonstrated beneficial effects of such strategies.
Concluding remarks
Considerable progress has been made in demonstrating inflammatory and autoimmune mechanisms in PAH. However, no major autoantigen involved in disease pathogenesis has been clearly defined and the precise mechanisms by which inflammation triggers and sustains vascular remodeling and, as a consequence, heart failure remain to be clarified. Although in the monocrotaline-induced PH rat model kinetics studies have clearly shown that inflammation precedes vascular remodeling [58], there is no chronic
Conflicts of interest
Professor Humbert has served as an advisory board member for Actelion, Aires, Bayer, Novartis and Pfizer, and received consultancy and lecture fees from Actelion, Aires, Bayer, GlaxoSmithKline, Novartis and Pfizer. Dr Perros has a relationship with Bayer. He received an Investigator Sponsored Study (ISS) grant.
Acknowledgments
Sylvia Cohen-Kaminisky received funding from the Fondation pour la Recherche Médicale (FRM) (grant number: DEQ20100318257). Aurélie Hautefort is supported by a PhD grant from Région Ile de France (CORDDIM). Frédéric Perros receives funding from National Funding Agency for Research (ANR) (Grant: ANR-13-JSV1-001).
References (81)
Inflammation in pulmonary arterial hypertension
Chest
(2012)Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension
Chest
(2006)The prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophages
J. Biol. Chem.
(2002)Endothelial dysfunction and activation as an expression of disease: role of prostacyclin analogs
Int. Immunopharmacol.
(2005)Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus
Metabolism
(2003)Endothelin A receptor antagonist BSF-208075 causes immune modulation and neuroprotection after stroke in gerbils
Brain Res.
(2007)Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops
Blood
(2004)Gender-specific immunological effects of the phosphodiesterase 5 inhibitor sildenafil in healthy mice
Mol. Immunol.
(2013)- et al.
Phosphodiesterase inhibitors in the management of autoimmune disease
Autoimmun. Rev.
(2010) Interleukin-6: from an inflammatory marker to a target for inflammatory diseases
Trends Immunol.
(2012)